v3.26.1
Revenue - Schedule of Disaggregation of Revenue by Product (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Disaggregation of Revenue [Line Items]    
Revenue $ 19,799 $ 12,729
U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 12,119 8,489
Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 7,680 4,239
Cardiometabolic Health    
Disaggregation of Revenue [Line Items]    
Revenue 15,760 9,208
Cardiometabolic Health | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 9,924 6,577
Cardiometabolic Health | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 5,836 2,631
Mounjaro    
Disaggregation of Revenue [Line Items]    
Revenue 8,662 3,842
Mounjaro | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 4,232 2,656
Mounjaro | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 4,430 1,186
Zepbound    
Disaggregation of Revenue [Line Items]    
Revenue 4,160 2,312
Zepbound | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 4,134 2,305
Zepbound | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 26 7
Jardiance    
Disaggregation of Revenue [Line Items]    
Revenue 1,114 1,014
Jardiance | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 512 310
Jardiance | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 602 705
Trulicity    
Disaggregation of Revenue [Line Items]    
Revenue 919 1,095
Trulicity | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 600 771
Trulicity | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 318 325
Other cardiometabolic health    
Disaggregation of Revenue [Line Items]    
Revenue 905 945
Other cardiometabolic health | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 446 535
Other cardiometabolic health | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 460 410
Oncology    
Disaggregation of Revenue [Line Items]    
Revenue 2,268 1,948
Oncology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 1,228 1,046
Oncology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 1,040 902
Verzenio    
Disaggregation of Revenue [Line Items]    
Revenue 1,302 1,159
Verzenio | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 706 658
Verzenio | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 596 501
Other oncology    
Disaggregation of Revenue [Line Items]    
Revenue 966 789
Other oncology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 522 388
Other oncology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 444 400
Immunology    
Disaggregation of Revenue [Line Items]    
Revenue 1,203 1,088
Immunology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 619 578
Immunology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 584 510
Taltz    
Disaggregation of Revenue [Line Items]    
Revenue 733 762
Taltz | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 417 477
Taltz | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 315 285
Other immunology    
Disaggregation of Revenue [Line Items]    
Revenue 470 326
Other immunology | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 202 102
Other immunology | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 269 225
Neuroscience    
Disaggregation of Revenue [Line Items]    
Revenue 382 272
Neuroscience | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 293 189
Neuroscience | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 89 83
Other    
Disaggregation of Revenue [Line Items]    
Revenue 187 213
Other | U.S.    
Disaggregation of Revenue [Line Items]    
Revenue 56 100
Other | Outside U.S.    
Disaggregation of Revenue [Line Items]    
Revenue $ 130 $ 113